Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Experience with post-transplant cyclophosphamide (PTCy) for GVHD prophylaxis in HLA-matched related donor HSCT in pediatric and adult patients. evidence of real-life outcomes from a Latin American transplant center.

View Full Paper
Ask AI
Bookmark
Share

Authors

AAAraceli Leal AlanisUniversidad Metropolitana de Monterrey

Discussion

Loading...

Member takes

Implication

Demonstrates effective GVHD prophylaxis in pediatric and adult patients, indicating promising outcomes for those undergoing allogeneic transplants.

Key Points

  • GVHD prophylaxis with post-transplant cyclophosphamide yielded low incidence of severe acute and chronic GVHD.
  • Cumulative incidence of GVHD was 31% at 1 year and 36% at 2 years, showing manageable outcomes.
  • Observational analysis of 43 patients revealed one- and two-year overall survival rates of 69% and 62%, respectively.
  • The findings suggest that male donors under 30 years may further reduce GVHD incidence in transplants.

Cite This Study

Araceli Leal Alanis (2025) studied this question.

synapsesocial.com/papers/69362f604fa91c937236dd02https://doi.org/10.1182/blood-2025-7717
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Post-transplant cyclophosphamide (PTCy) versus other graft-versus-host disease prophylaxis strategies in reduced intensity allogeneic stem cell transplantation from related and matched unrelated donors in patients with acute myeloid leukemia and myelodysplastic syndromes: A study from the french society of bone marrow transplantation (SFGM-TC) registry2025
  2. 2Outcomes after bone marrow versus peripheral blood mismatched unrelated donor hematopoietic cell transplantation using posttransplant cyclophosphamide-based GVHD prophylaxis2025
  3. 3Chronic graft-versus-host disease in the era of post-transplant cyclophosphamide2026 · 5 citations
  4. 4Safety and efficacy of post transplant cyclophosphamide vs tacrolimus plus methotrexate for gvhd prophylaxis in myelofibrosis2025
  5. 5Post-transplant cyclophosphamide improves survival compared to antithymocyte globulin in HLA-mismatched unrelated donor stem cell transplantation2025 · 1 citations